Pfizer Discontinues Oral GLP-1 Drug Development
Pfizer Inc. has decided to discontinue the development of danuglipron, an oral GLP-1 receptor agonist investigated for chronic weight management.
NEW YORK – Pfizer Inc. announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was being investigated for chronic weight management.
The decision followed a review of clinical data and discussions with regulators. While dose-optimization studies met key pharmacokinetic objectives and confirmed a potential for competitive efficacy and tolerability, one participant in a study experienced potential drug-induced liver injury. This condition resolved after discontinuation of the drug. Although the overall frequency of liver enzyme elevations in danuglipron's safety database of over 1,400 participants aligns with approved agents in the GLP-1 class, this single instance contributed to the development halt.
"Cardiovascular and metabolic diseases, including obesity, remain important areas of unmet medical need," said Chris Boshoff, Pfizer's Chief Scientific Officer and President, Research and Development. "While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs." Pfizer is advancing other obesity programs, including a GIPR antagonist candidate.
Data from the danuglipron clinical development program will be presented at a scientific forum or submitted for publication in a peer-reviewed journal. Pfizer continues its focus on discovering new treatments for obesity and other diseases.